HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CHPA

This article was originally published in The Tan Sheet

Executive Summary

Trade group brings anti-meth educational program to retailers in Missouri, where new law effective Aug. 28 limits sales of OTCs containing ephedrine, pseudoephedrine or PPA to three packages or 9 g total. CHPA posters and brochures sent to Missouri Retailers Association, Missouri Petroleum Marketers & Convenience Store Association and Retail Grocers Association of Greater Kansas City for distribution. Posters explain new law, warn retailers against attempting to detain methamphetamine abusers. Program is similar to one recently launched in Arkansas (1"The Tan Sheet" Aug. 20, In Brief)

You may also be interested in...



Meth class

CHPA in discussion with states of Washington, Oregon, Missouri about education programs on laws limiting OTC purchases of potential methamphetamine precursors. Trade association is launching effort in Arkansas this month, where new law limits amount of ephedrine, pseudoephedrine or PPA that may be purchased in one transaction to three packages or 9 g, whichever is smaller; bill also prohibits sales to minors. Program includes seminars in collaboration with DEA, state Health Department, as well as educational posters and brochures distributed to pharmacies. CHPA conducted similar retailer education program in Nevada last year (1"The Tan Sheet," June 5, 2000, p. 6)

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS131494

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel